New antifungal drug APX001 passes first safety check in humans

NCT ID NCT02956499

Completed Disease control Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested the safety and tolerability of a new antifungal drug called APX001 in 200 healthy volunteers. Participants received either single or multiple doses of the drug or a placebo. The study focused on side effects and how the drug moves through the body, not on treating infections. It is a necessary first step before testing the drug in patients with fungal infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APX001
What this could lead to: If successful, this could lead to a new treatment option for serious fungal infections, especially for patients who don't respond to current medicines.
What could go wrong: This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing, not whether the drug actually works against infections. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fungal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FUNGAL INFECTION

Contacts and locations

Locations

PRA Health Sciences

Groningen, 9728 NZ, Netherlands
PRA Health Sciences

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.